New combo shows promise for tough lung cancer
NCT ID NCT06478043
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tested a combination of two drugs—ivonescimab (AK112) and irinotecan liposome—in 60 people with extensive-stage small-cell lung cancer whose disease had worsened after standard first-line therapy. The goal was to see if the combo could slow cancer growth and shrink tumors. Participants received the drugs intravenously every 2 to 3 weeks. The study is now complete, and results will show how well the treatment worked and what side effects occurred.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ivonescimab (AK112) and irinotecan liposome
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced small-cell lung cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase study with only 60 participants and no comparison group, so results may not apply broadly. The drugs can cause serious side effects like low blood cell counts and immune-related reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink tough lung cancers?
- Can a smartphone app ease the burden of advanced lung cancer?
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
- New hope for tough lung cancer: combo therapy enters phase II trial
- New chemo combo shows promise for tough lung cancer